Under a tenth of people who could benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it publishes its first guidance on the medications.
Considering over a billion individuals worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
According to forecasts, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that excess weight is a lifelong illness that can be addressed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key barriers to universal availability to the treatments that can help people shift substantial weight, explains the body.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic outlook, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization.
The advice encourages governments and firms to expand availability, by measures like licensing agreements.
A patent on a key compound – the core component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and boost satiety so users reduce food intake.
Individuals typically see weight reduction in the initial weeks of starting on the weekly injections.
Studies indicates people may regain a significant portion after a year of discontinuing the medication, as their typical appetite return.
To be carrying excess weight increases your risk for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
